Enveric Biosciences reports Q2 2024 net loss of $1.7M; prioritizes EB-003 as lead candidate

Enveric Biosciences, Inc.

2024-Q2 EPS reported -$0.75 vs consensus -$100.98 ▲ beat (+99.3%)

Net loss of $1.7M ($0.23/share) vs $6.4M loss in Q2 2023; cash on hand $3.5M.
Prioritized EB-003, a non-hallucinogenic neuroplastogenic molecule, as lead development candidate.
Preclinical data confirms oral bioavailability and brain exposure of EB-003; IND filing expected Q3 2025.
Signed licensing agreement with Aries Science & Technology for radiation dermatitis product; non-binding term sheets for joint disease and cancer treatments.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.